💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Irbesartan

CHEMBL1513 Phase 4 승인됨 Small molecule
Half-Life
11-15 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
428.5 g/mol
LogP
4.1
Phase
4

This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

분자량

428.5320 g/mol

LogP

4.10

TPSA

87.10 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Cardiovascular Disease Chronic Kidney Disease Stroke Hyperlipidemia Obesity Type 2 Diabetes Hypertension Hepatitis C Heart Failure Atrial Fibrillation

약물 분류

C — C - Cardiovascular System

작용 기전

Selective non-competitive angiotensin II type 1 receptor antagonist.

Pharmacokinetics (PK)

Half-Life 11-15 hours

Pharmacodynamics (PD)

기전

Selective non-competitive angiotensin II type 1 receptor antagonist.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H28N6O

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
회전 가능 결합

                        
7

                    

                    
                    
                    

                        
무거운 원자

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This angiotensin II receptor blocker (ARB) is used to treat high blood pressure, heart failure, and kidney disease in patients with type 2 diabetes. It works by blocking the AT1 receptor for angiotensin II, causing blood vessels to relax and reducing aldosterone secretion. It is often used in patients who cannot tolerate ACE inhibitors due to cough.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective non-competitive angiotensin II type 1 receptor antagonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Irbesartan: Half-life: 11-15 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Irbesartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1513.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3749.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.